Table 2.

Comparisons of the SF-McGill-Q and m-NRS responses in patients treated with bumetanide

Variables	Number of Items	Item Number	Mean±SD			MMA
			Baseline (n=11)	After 2 Months (n=11)	After 4 Months (n=9)	F	P
Continuous	6	1, 5, 6, 8, 9, 10	7.11±1.20	6.41±1.06	5.18±1.01	3.286	0.09
Intermittent	6	2, 3, 4, 11, 16, 18	5.23±1.37	4.56±1.29	4.26±1.22	2.888	0.1
Neuropathic	6	7, 17, 19, 20, 21, 22	5.68±2.46	4.17±1.74	3.25±1.35	94.237	0.001
Affective	4	12, 13, 14, 15	7.12±0.81	6.62±0.80	6.3±0.89	2.331	0.14
Total	22		6.2±1.83	5.33±1.68	4.80±1.67	13.138	0.002
NRS Total			7.81±0.87	5.45±1.32	4.22±1.25	3.286	0.048

P-values were calculated using Mixed Model Analysis (MMA). Each item in four parts of SF-McGill-Q of continuous, intermittent, neuropathic, and affective is rated based on a 0–10 scale with 0 equal to no pain and 10 equal to the worst pain.

SF-McGill-Q: Short-Form McGill pain Questionnaire; m-NRS: Modified Numerical Rating Scale.